Impact of Metformin Use on Survival in Locally-advanced, Inoperable Non-small Cell Lung Cancer Treated with Definitive Chemoradiation

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2015 Apr 30

PMID 25922712

Citations 26

Authors

Inaya Ahmed

Adam Ferro

Alan Cohler

John Langenfeld

Sujani G Surakanti

Joseph Aisner

Wei Zou

Bruce G Haffty

Salma K Jabbour

Affiliations

Soon will be listed here.

Abstract

Background: We investigated survival outcomes in diabetic patients with non-small cell lung cancer (NSCLC) treated with concurrent metformin and definitive chemoradiation.

Methods: This single-institution, retrospective cohort study included 166 patients with NSCLC who were treated definitively with chemoradiation between 1999 and 2013. Of 40 patients who had type II diabetes, 20 (50%) were on metformin, and 20 (50%) were not on metformin. The primary outcome was overall survival (OS), and secondary outcomes included progression-free survival (PFS), locoregional recurrence-free survival (LRRFS) and distant metastasis-free survival (DMFS). Kaplan Meier method and log-rank test were performed in survival analysis. Cox regression was utilized in univariate analysis of potential confounders.

Results: Median follow-up was 17.0 months. Compared with non-diabetic patients, diabetic patients on metformin demonstrated similar OS (16.3 vs. 14.3 mo, P=0.23), PFS (11.6 vs. 9.7 mo, P=0.26), LRRFS (14.1 vs. 11.9 mo, P=0.78), and DMFS (13.4 vs. 10.0 mo, P=0.69). Compared with diabetic patients not on metformin, diabetic patients on metformin also exhibited similar OS (14.3 vs. 19.2 mo, P=0.18), PFS (19.7 vs. 10.1 mo, P=0.38), LRRFS (11.9 vs. 15.5 mo, P=0.69), and DMFS (10.0 vs. 17.4 mo, P=0.12). Identified negative prognostic factors on included squamous cell histology, lower performance status, higher T stage, and non-caucasian ethnicity.

Conclusions: No statistically significant differences in survival or patterns of failure were found among the three cohorts in this small set of patients. No statistically significant differences in survival or patterns of failure were found between the three cohorts in this small set of patients. Though it is possible that metformin use may in fact have no effect on survival in NSCLC patients treated with definitive RT, larger-scale retrospective and prospective studies are implicated for clarification.

Citing Articles

Evaluation of the effect of metformin as a radiosensitiser in solid tumours: A systematic review.

Portillo E, Olivares-Hernandez A, Corral Gudino L, Felix L, Hernandez L, Dominguez L Clin Transl Radiat Oncol. 2025; 52:100930.

PMID: 40028423 PMC: 11871473. DOI: 10.1016/j.ctro.2025.100930.

Neighborhood deprivation in relation to lung cancer in individuals with type 2 diabetes-A nationwide cohort study (2005-2018).

Li X, Jansaker F, Sundquist J, Crump C, Hamano T, Sundquist K PLoS One. 2023; 18(7):e0288959.

PMID: 37478113 PMC: 10361504. DOI: 10.1371/journal.pone.0288959.

Efficacy of metformin adjunctive therapy as the treatment for non-diabetic patients with advanced non-small cell lung cancer: A Systematic review and Meta-analysis.

Duan X, Liao B, Liu X, Chen R J Res Med Sci. 2023; 28:45.

PMID: 37405073 PMC: 10315409. DOI: 10.4103/jrms.jrms_792_22.

Addition of metformin for non-small cell lung cancer patients receiving antineoplastic agents.

Wang Y, Hu Y, Wang T, Che G, Li L Front Pharmacol. 2023; 14:1123834.

PMID: 36969876 PMC: 10036803. DOI: 10.3389/fphar.2023.1123834.

Association of Diabetes Severity and Mortality with Lung Squamous Cell Carcinoma.

Su C, Chen W, Chen M, Shia B, Wu S Cancers (Basel). 2022; 14(10).

PMID: 35626156 PMC: 9139965. DOI: 10.3390/cancers14102553.

References

Skinner H, McCurdy M, Echeverria A, Lin S, Welsh J, OReilly M . Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol. 2012; 52(5):1002-9. DOI: 10.3109/0284186X.2012.718096. View

Ashworth A, Rodrigues G, Boldt G, Palma D . Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer. 2013; 82(2):197-203. DOI: 10.1016/j.lungcan.2013.07.026. View

Mogi A, Kuwano H . TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol. 2011; 2011:583929. PMC: 3035360. DOI: 10.1155/2011/583929. View

Jiralerspong S, Palla S, Giordano S, Meric-Bernstam F, Liedtke C, Barnett C . Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009; 27(20):3297-302. PMC: 2736070. DOI: 10.1200/JCO.2009.19.6410. View

Sandulache V, Hamblin J, Skinner H, Kubik M, Myers J, Zevallos J . Association between metformin use and improved survival in patients with laryngeal squamous cell carcinoma. Head Neck. 2013; 36(7):1039-43. DOI: 10.1002/hed.23409. View

Weichselbaum R, Hellman S . Oligometastases revisited. Nat Rev Clin Oncol. 2011; 8(6):378-82. DOI: 10.1038/nrclinonc.2011.44. View

Reck M, Heigener D, Mok T, Soria J, Rabe K . Management of non-small-cell lung cancer: recent developments. Lancet. 2013; 382(9893):709-19. DOI: 10.1016/S0140-6736(13)61502-0. View

DeCensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B . Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010; 3(11):1451-61. DOI: 10.1158/1940-6207.CAPR-10-0157. View

Cossor F, Adams-Campbell L, Chlebowski R, Gunter M, Johnson K, Martell R . Diabetes, metformin use, and colorectal cancer survival in postmenopausal women. Cancer Epidemiol. 2013; 37(5):742-9. PMC: 3769471. DOI: 10.1016/j.canep.2013.04.015. View

10.

Dowling R, Zakikhani M, Fantus I, Pollak M, Sonenberg N . Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007; 67(22):10804-12. DOI: 10.1158/0008-5472.CAN-07-2310. View

11.

Bailey C, Turner R . Metformin. N Engl J Med. 1996; 334(9):574-9. DOI: 10.1056/NEJM199602293340906. View

12.

Romero I, McCormick A, McEwen K, Park S, Karrison T, Yamada S . Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 2011; 119(1):61-7. PMC: 3244683. DOI: 10.1097/AOG.0b013e3182393ab3. View

13.

Barone B, Yeh H, Snyder C, Peairs K, Stein K, Derr R . Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008; 300(23):2754-64. PMC: 3093051. DOI: 10.1001/jama.2008.824. View

14.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30. DOI: 10.3322/caac.21166. View

15.

Jabbour S, Daroui P, Moore D, Licitra E, Gabel M, Aisner J . A novel paradigm in the treatment of oligometastatic non-small cell lung cancer. J Thorac Dis. 2012; 3(1):4-9. PMC: 3256496. DOI: 10.3978/j.issn.2072-1439.2010.12.09. View

16.

Skinner H, Crane C, Garrett C, Eng C, Chang G, Skibber J . Metformin use and improved response to therapy in rectal cancer. Cancer Med. 2013; 2(1):99-107. PMC: 3797563. DOI: 10.1002/cam4.54. View

17.

Edwards B, Ward E, Kohler B, Eheman C, Zauber A, Anderson R . Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2009; 116(3):544-73. PMC: 3619726. DOI: 10.1002/cncr.24760. View

18.

Hwang A, Haynes K, Hwang W, Yang Y . Metformin and survival in pancreatic cancer: a retrospective cohort study. Pancreas. 2013; 42(7):1054-9. PMC: 3779343. DOI: 10.1097/MPA.0b013e3182965a3c. View

19.

Algire C, Zakikhani M, Blouin M, Shuai J, Pollak M . Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer. 2008; 15(3):833-9. DOI: 10.1677/ERC-08-0038. View

20.

Tan B, Yao W, Ge J, Peng X, Du X, Zhang R . Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer. 2011; 117(22):5103-11. DOI: 10.1002/cncr.26151. View